12:00 AM
Apr 19, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CB-183: Phase II started

Cubist began a double-blind, dose-ranging, U.S. and Canadian Phase II trial to evaluate 125 and 250 mg oral CB-183,315 given twice daily...

Read the full 90 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >